On this basis, we reasonably question whether early-stage TNBC patients would benefit from NExT regardless of PDL1 status as reported for atezolizumab [76], or it would be of interest for the treatment of advanced disease with PDL1 positivity, where a careful choice of chemotherapeutics should be made first to facilitate the upregulation of PDL1 in the tumor tissue to increase the tumor sensitivity to NExT [65]. Here, CD274 is linked to neoplasm.